Ken Griffin
CMPX icon

Ken Griffin’s Compass Therapeutics CMPX Stock Holding History

Ken Griffin’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$505K Buy
+95,500
New +$551K ﹤0.01% 9279
2025
Q3 		– Sell
-12,400
Closed -$32.2K – 12901
2025
Q2 		$32.2K Sell
12,400
-157,200
-93% -$324K ﹤0.01% 11956
2025
Q1 		$322K Buy
+169,600
New +$451K ﹤0.01% 9421

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ken Griffin's CMPX Position: Q1 2026 in Review

Ken Griffin increased its Compass Therapeutics (CMPX) stake by 583% in Q1 2026, buying an estimated $3.55M and bringing the position to 721,410 shares worth $3.82M. The position accounts for ﹤0.01% of the portfolio, ranked #4799.

Ken Griffin first reported a position in CMPX in Q4 2021 and has held it in 10 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Ken Griffin held 721,410 shares of Compass Therapeutics worth $3.82M as of Q1 2026.
  • Ken Griffin bought 615,728 Compass Therapeutics shares in Q1 2026, an estimated $3.55M.
  • Compass Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #4799 holding.
  • Ken Griffin first reported a position in Compass Therapeutics in Q4 2021 and has held it in 10 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.